Therapeutic area: Metabolic Disorders
Sibnayal® :
Active substances : potassium citrate and potassium hydrogen carbonate
Dosages :
- Sibnayal 8 mEq, prolonged-release granules
- Sibnayal 24 mEq, prolonged-release granules
Conditions of supply and use :
- Medicinal product subject to medical prescription.
SIBNAYAL® has been approved by EMA in April 30th, 2021.
For more information about Sibnayal® please use the link below:
SIBNAYAL® has been approved by MHRA in June, 2021.
Advicenne signed partnerships with several companies for the commercialisation of Sibnayal® in Europe : FrostPharma AB for the Nordic Region of Europe, TwinPharma for Benelux, ExCEEd Orphan for Central and Eastern Europe, SPA Farma for Italy, Spain and Portugal and Avanzanite Bioscience BV for Germany, Austria, Switzerland, Liechtenstein and Greece.